ABBVAbbVieSigning up patients
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Gynecologic Cancers · Platinum-Sensitive Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer (PSOC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 377 (planned)
- Started
- Jul 30, 2025
- Main results expected
- Jan 2028
- Fully finished
- Feb 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Dose-limiting Toxicities (DLTs)
Measured over: Up to approximately 3 years
Percentage of Participants with Adverse Events (AE)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07024784 · record last updated 2026-10-01 · checked 2026-11-09 15:47 UTC